29,280 Shares in Sensus Healthcare, Inc. (NASDAQ:SRTS) Acquired by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC bought a new stake in Sensus Healthcare, Inc. (NASDAQ:SRTS) in the 2nd quarter, HoldingsChannel reports. The firm bought 29,280 shares of the company’s stock, valued at approximately $156,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Renaissance Technologies LLC grew its holdings in shares of Sensus Healthcare by 34.4% in the second quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock valued at $2,087,000 after purchasing an additional 100,294 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Sensus Healthcare by 128.0% in the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after acquiring an additional 93,511 shares during the last quarter. Marshall Wace LLP grew its position in Sensus Healthcare by 152.4% in the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock worth $412,000 after acquiring an additional 46,732 shares during the period. Hillsdale Investment Management Inc. purchased a new position in Sensus Healthcare in the first quarter worth approximately $155,000. Finally, Acadian Asset Management LLC increased its stake in Sensus Healthcare by 578.6% during the second quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock worth $239,000 after acquiring an additional 38,474 shares during the last quarter. 25.30% of the stock is owned by institutional investors and hedge funds.

Sensus Healthcare Stock Down 2.0 %

SRTS opened at $6.42 on Wednesday. Sensus Healthcare, Inc. has a 52 week low of $1.79 and a 52 week high of $7.18. The business has a fifty day simple moving average of $6.22 and a 200-day simple moving average of $5.43. The firm has a market cap of $105.24 million, a P/E ratio of 22.14 and a beta of 1.05.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.03 by $0.07. Sensus Healthcare had a net margin of 18.27% and a return on equity of 13.46%. The business had revenue of $9.24 million during the quarter, compared to analyst estimates of $7.00 million. During the same quarter last year, the firm posted ($0.02) earnings per share. Sell-side analysts expect that Sensus Healthcare, Inc. will post 0.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on SRTS. Roth Capital upgraded Sensus Healthcare to a “strong-buy” rating in a report on Friday, July 12th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Sensus Healthcare in a research note on Monday, August 12th.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.